The GIP receptor activation in tirzepatide may actually moderate some GLP-1-related GI effects, and many users report that tirzepatide is slightly better tolerated gastrointestinally than semaglutide despite being more effective
Currently, the only GLP-1 dual-target drug with an oral version is Vikings VK2735, which is still in Phase I clinical trials
It can present as a slow drift: less resilience, less training response, more fatigue, and a body that feels harder to steer
But certain symptoms warrant immediate medical attention: severe abdominal pain that does not resolve, persistent vomiting that prevents hydration, signs of pancreatitis (intense upper abdominal pain radiating to the back), or any allergic reaction symptoms
It has exhibited DPP-IV action along with its cardioprotective effects, reduced glycated Hb level, enhanced antioxidant action, and regulated glucose homeostasis (124, 149, 150)
The goal is steady, sustainable progress that fits your life, not a quick fix